Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Gengpeng Lin"'
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Next-generation sequencing technology has enabled the identification of fusion partners of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer, and various ALK fusion partners have been confirmed. Here, a novel rhabdomyosarcoma 2-associate
Externí odkaz:
https://doaj.org/article/1de5b4c8dfa94ea6ae3b2f1f38a8381d
Autor:
Wan He, Gengpeng Lin, Chaohu Pan, Wenwen Li, Jing Shen, Yangli Liu, Hui Li, Dongfang Wu, Xuejia Lin
Publikováno v:
Frontiers in Genetics, Vol 13 (2022)
Externí odkaz:
https://doaj.org/article/82d8120692e147f2b88e74ab12990a71
Autor:
Wan He, Gengpeng Lin, Chaohu Pan, Wenwen Li, Jing Shen, Yangli Liu, Hui Li, Dongfang Wu, Xuejia Lin
Publikováno v:
Frontiers in Genetics, Vol 13 (2022)
Background: RNA modification plays an important role in many diseases. A comprehensive study of tumor microenvironment (TME) characteristics mediated by RNA modification regulators will improve the understanding of TME immune regulation.Methods: We s
Externí odkaz:
https://doaj.org/article/ba9de205044d4ad1be368f45a1a81015
Autor:
Zhimin Zeng, Yuxia Liang, Jia Shi, Lisha Xiao, Lu Tang, Yubiao Guo, Fengjia Chen, Gengpeng Lin
Publikováno v:
Diagnostics, Vol 12, Iss 11, p 2891 (2022)
Background: Long non-coding RNA (lncRNA) participates in the immune regulation of lung cancer. However, limited studies showed the potential roles of immune-related lncRNAs (IRLs) in predicting survival and immunotherapy response of lung adenocarcino
Externí odkaz:
https://doaj.org/article/136fa6c5f3454728b4dd9db5ea55b90f
Publikováno v:
American Journal of Physiology-Lung Cellular and Molecular Physiology. 321:L6-L16
Macrophage migration inhibitory factor (MIF) inhibition can attenuate pulmonary fibrosis, but the antifibrotic mechanism is unclear. Here we investigated the antifibrotic effect of MIF knockdown in rats with bleomycin (BLM)-induced pulmonary fibrosis
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease. 14:2663-2671
Background Biotherapy for asthma may be useful in patients suffering from chronic obstructive pulmonary disease (COPD) with asthma characteristics. Therefore, the evaluation and close monitoring of asthma characteristics in severe and extremely sever
Publikováno v:
Clinical Lung Cancer. 22:e157-e159
Clinical Practice Points • Osimertinib is widely used in patients with lung cancer with EGFR T790M after EGFR TKI treatment with high efficacy and approved in first-line treatment for all EGFR positive patients. However, the resistance profile to o
Publikováno v:
Frontiers in Oncology; 8/1/2022, Vol. 12, p1-5, 5p
Publikováno v:
Annals of palliative medicine. 9(6)
BACKGROUND Quality of life (QOL) is one of the most important endpoints in lung cancer care. Both nutritional and immune status reportedly correlate with QOL, so we investigated whether the prognostic nutritional index (PNI), a reliable marker of nut
Publikováno v:
Journal of Thoracic Oncology. 16:S36-S37